Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician

Not since the late 1990s with the arrival of highly active anti-retroviral therapy for HIV has there been such an explosion of new compounds and regimens in the field of virology. The slow beginnings of this new era, the direct-acting antiviral (DAA) therapy for hepatitis C, started a few years ago with the first protease inhibitors, boceprevir and telaprevir, each being paired with interferon and ribavirin, leading to a significant improvement in response rates, but only in the easiest-to-cure population of treatment-naïve patients with genotype 1 virus.
Source: Clinics in Liver Disease - Category: Gastroenterology Authors: Tags: Preface Source Type: research